Kymera Therapeutics (KYMR) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
012M25M38M50M62M75M88M100MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
05001K2K2K2K3K4K4KQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development ExpensesGeneral And Administrative ExpensesOther Expenses
038M75M112M150M188M225M262M300MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
-100M-87M-75M-62M-50M-37M-25M-12M1Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

Revenue Variation (%)

Revenue Variation
-901714326949551K1K2K2KQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
03875112150188225262300Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
-80-45-10256095130165200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
02505007501K1K2K2K2KQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
-40-35-30-25-20-14-9-41Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
05M10M15M20M25M30M35M40MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
💰 Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
0510152025303540Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Cash Flow to Debt Ratio

Cash At End Of Period
062M125M188M250M312M375M438M500MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
🏦 Balance Sheet
📈 Key Metrics